Skip to main content
. 2022 May 30;13:860784. doi: 10.3389/fphar.2022.860784

FIGURE 2.

FIGURE 2

shows the mean central macular thickness (CMT) at baseline and for each fellow up visit after switching to brolucizumab. p values refer to statistical differences between each time points and baseline.